Revvity’s Software Acquisition Strategy Extends Its Analytical Characterization Reach

Introduction

Revvity is expanding its scientific software capabilities through a targeted acquisition strategy, with its purchase of Advanced Chemistry Development, Inc. (ACD/Labs) representing a major step in strengthening its analytical characterization and molecular-design portfolio.

The acquisition, completed after fiscal 2025, brought ACD/Labs into Revvity’s Life Sciences segment. Revvity paid $72 million in cash at closing, with up to an additional $8 million in contingent consideration linked to revenue milestones through 2028. ACD/Labs has approximately 200 employees and is based in Toronto, Canada.

ACD/Labs Adds Specialized Analytical Capabilities

ACD/Labs develops scientific software supporting analytical characterization and molecular design across pharmaceutical and materials science markets.

Its technologies help scientists identify and characterize molecules, analyze complex spectral information, predict molecular properties, monitor purity and quality, and support chemical and pharmaceutical development workflows.

The company's portfolio includes the Spectrus Platform for spectral analysis, Percepta for molecular property and ADMET prediction, Katalyst D2D for high-throughput experimentation, Luminata for pharmaceutical chemistry and manufacturing decision support, and ADMS for enterprise analytical data management.

These capabilities give Revvity additional depth in areas where analytical data must be transformed into useful scientific insights.

Strengthening Revvity Signals

A central objective of the acquisition is to expand Revvity Signals, the company's scientific software business.

Revvity has positioned the combination as a way to connect molecular design, analytical science, development, and manufacturing workflows within a more unified digital environment. The company said ACD/Labs' technologies can help bridge the gap between analytical data and actionable insights.

This is strategically important as pharmaceutical and chemical organizations increasingly seek software platforms that can connect information across different stages of research rather than keeping analytical data isolated in separate systems.

From Analytical Data to Scientific Decisions

Modern laboratories generate large quantities of information through spectroscopy, experimentation, molecular modeling, quality analysis, and other techniques. Simply collecting this information is not enough; researchers also need to interpret it and use it to make decisions.

ACD/Labs' analytical software gives Revvity an opportunity to strengthen this part of the scientific workflow.

The combination can support a progression from molecular design and experimentation to analytical characterization, development, scale-up, and manufacturing. This broader workflow is consistent with Revvity's objective of providing connected solutions across the research and development lifecycle.

The Acquisition Fits Revvity’s Broader Software Strategy

The ACD/Labs transaction is not an isolated move. Revvity's corporate strategy includes expanding its offerings through both research and development investment and acquisitions of innovative technology.

This approach allows Revvity to add specialized capabilities more quickly while building a broader software ecosystem around its existing products.

The strategy is particularly relevant to scientific informatics, where customers increasingly want connected platforms that combine experimental data, analytical information, knowledge management, and decision-support tools.

Artificial Intelligence Adds Another Layer

Revvity's software strategy is also moving toward artificial intelligence and more advanced ways of interacting with scientific data.

In June 2026, the company launched Signals AI, an agentic framework built into the Signals One platform. The system allows scientists to interact with connected R&D data using natural language and is designed to turn scientific data and organizational knowledge into actionable insights.

The company subsequently expanded the Signals AI ecosystem through an integration with Anthropic's Claude, allowing scientists to access connected R&D knowledge through Claude using an MCP connector.

This development gives additional context to the ACD/Labs acquisition. As AI becomes increasingly important in scientific research, high-quality analytical and molecular data becomes an important foundation for generating useful AI-driven insights.

Implications for Pharmaceutical and Chemical R&D

The acquisition has particular significance for pharmaceutical and chemical companies, where analytical characterization is essential throughout research and development.

Scientists need to understand molecular structures, assess purity, interpret analytical results, predict properties, and make decisions about development and manufacturing. Software that connects these activities can potentially reduce data fragmentation and improve research productivity.

For pharmaceutical organizations, this could support workflows from early discovery through development and manufacturing. For chemical and materials companies, similar capabilities can help researchers manage increasingly complex molecular and analytical information.

A Targeted $72 Million Investment

The financial structure of the acquisition demonstrates that Revvity made a relatively focused investment to obtain specialized software capabilities.

The company paid $72 million at closing, while the additional consideration of up to $8 million depends on the achievement of specified revenue metrics through 2028.

The transaction therefore combines an upfront investment with a performance-linked component, allowing part of the potential additional payment to depend on the future performance of the acquired business.

Why Analytical Characterization Matters

Analytical characterization sits at the center of many scientific workflows. Researchers cannot effectively develop or manufacture products without understanding what materials and molecules they are working with and how those materials behave.

As scientific datasets become larger and more complex, analytical software becomes increasingly important for organizing, interpreting, and connecting this information.

By adding ACD/Labs, Revvity gains specialized technology in an area that complements its broader research informatics strategy. The acquisition can therefore be viewed as an effort to strengthen the data and analytical foundation underlying its software ecosystem.

Outlook for Revvity’s Software Business

Revvity's continued investment in Signals, AI capabilities, and scientific software suggests that informatics will remain an important part of its long-term strategy.

The company reported $730 million in second-quarter 2026 revenue, with 4% pro forma revenue growth and 3% pro forma organic revenue growth, while also raising its full-year guidance.

While ACD/Labs is relatively small compared with Revvity's overall business, its specialized capabilities could have strategic importance beyond the size of the transaction.

The value of the acquisition will ultimately depend on how effectively Revvity integrates ACD/Labs' technology, combines its analytical capabilities with Signals, and converts these capabilities into customer adoption and recurring software revenue.

Conclusion

Revvity's acquisition of ACD/Labs represents a strategic expansion of its scientific software portfolio and strengthens its position in analytical characterization, molecular design, and research informatics.

The combination of ACD/Labs' specialized analytical technologies with Revvity Signals creates an opportunity to connect scientific information across discovery, development, scale-up, and manufacturing.

At the same time, Revvity's growing investment in AI through Signals AI indicates that the company is building toward a broader digital research ecosystem in which analytical data, molecular intelligence, and artificial intelligence work together.

As pharmaceutical, biotechnology, chemical, and materials companies continue their digital transformation, Revvity's software acquisition strategy could help it capture a larger role in how scientific organizations manage, interpret, and act on complex R&D data.